A current perspective on stereotactic body radiation therapy for pancreatic cancer.
Pancreatic cancer is a formidable malignancy with poor outcomes. The majority of patients are unable to undergo resection, which remains the only potentially curative treatment option. The management of locally advanced (unresectable) pancreatic cancer is controversial; however, treatment with either chemotherapy or chemoradiation is associated with high rates of local tumor progression and metastases development, resulting in low survival rates. An emerging local modality is stereotactic body radiation therapy (SBRT), which uses image-guided, conformal, high-dose radiation. SBRT has demonstrated promising local control rates and resultant quality of life with acceptable rates of toxicity. Over the past decade, increasing clinical experience and data have supported SBRT as a local treatment modality. Nevertheless, additional research is required to further evaluate the role of SBRT and improve upon the persistently poor outcomes associated with pancreatic cancer. This review discusses the existing clinical experience and technical implementation of SBRT for pancreatic cancer and highlights the directions for ongoing and future studies.
Department of Radiation Oncology, Duke University, Durham, NC, USA.
Julian C
JC
Hong
Department of Radiation Oncology, Duke University, Durham, NC, USA.
Brian G
BG
Czito
Department of Radiation Oncology, Duke University, Durham, NC, USA.
Christopher G
CG
Willett
Department of Radiation Oncology, Duke University, Durham, NC, USA.
Manisha
M
Palta
SBRT; pancreatic cancer; radiation therapy; stereotactic body radiation therapy